The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma

分子和组织学综合分析定义了食管鳞状细胞癌的亚型

阅读:4
作者:Guozhong Jiang # ,Zhizhong Wang # ,Zhenguo Cheng # ,Weiwei Wang # ,Shuangshuang Lu ,Zifang Zhang ,Chinedu A Anene ,Faraz Khan ,Yue Chen ,Emma Bailey ,Huisha Xu ,Yunshu Dong ,Peinan Chen ,Zhongxian Zhang ,Dongling Gao ,Zhimin Wang ,Jinxin Miao ,Xia Xue ,Pengju Wang ,Lirong Zhang ,Rathi Gangeswaran ,Peng Liu ,Louisa S Chard Dunmall ,Junkuo Li ,Yongjun Guo ,Jianzeng Dong ,Nicholas R Lemoine ,Wencai Li ,Jun Wang ,Yaohe Wang

Abstract

Esophageal squamous cell carcinoma (ESCC) is highly heterogeneous. Our understanding of full molecular and immune landscape of ESCC remains limited, hindering the development of personalised therapeutic strategies. To address this, we perform genomic-transcriptomic characterizations and AI-aided histopathological image analysis of 120 Chinese ESCC patients. Here we show that ESCC can be categorized into differentiated, metabolic, immunogenic and stemness subtypes based on bulk and single-cell RNA-seq, each exhibiting specific molecular and histopathological features based on an amalgamated deep-learning model. The stemness subgroup with signature genes, such as WFDC2, SFRP1, LGR6 and VWA2, has the poorest prognosis and is associated with downregulated immune activities, a high frequency of EP300 mutation/activation, functional mutation enrichment in Wnt signalling and the highest level of intratumoural heterogeneity. The immune profiling by transcriptomics and immunohistochemistry reveals ESCC cells overexpress natural killer cell markers XCL1 and CD160 as immune evasion. Strikingly, XCL1 expression also affects the sensitivity of ESCC cells to common chemotherapy drugs. This study opens avenues for ESCC treatment and provides a valuable public resource to better understand ESCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。